Genomics Through The Lens Of Precompetitive Data Sharing
With low-cost whole genome sequencing on the horizon, issues around acquiring and assessing large data sets of sequence information are front and center. The value proposition is also shifting, from the means of acquiring data to their interpretation. But finding a sustainable business model around data analysis and clinical services is far from straightforward.
You may also be interested in...
Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.
Tumor profiling is on the upswing, but prenatal genomic screening remains the largest translational application of whole genome sequencing. And now, the use of whole genome sequencing is spreading into the neonatal arena.
After a few months of sometimes-testy back and forth, Illumina seemingly has successfully fended off Roche’s hostile offer. But Roche is unlikely to give up on the sequencing tool maker entirely.